Literature DB >> 17524421

Computational characterization of structural role of the non-active site mutation M36I of human immunodeficiency virus type 1 protease.

Hirotaka Ode1, Shou Matsuyama, Masayuki Hata, Saburo Neya, Junko Kakizawa, Wataru Sugiura, Tyuji Hoshino.   

Abstract

A prominent characteristic of human immunodeficiency virus type 1 (HIV-1) is its high genetic variability, which generates diversity of the virus and often causes a serious problem of the emergence of drug-resistant mutants. Subtype B HIV-1 is dominant in advanced countries, and the mortality rate due to subtype B HIV-1 has been decreased during the past decade. In contrast, the number of patients with non-subtype B viruses is still increasing in developing countries. One of the reasons for the prevalence of non-subtype B viruses is lack of information about the biological and therapeutic differences between subtype B and non-subtype B viruses. M36I is the most frequently observed polymorphism in non-subtype B HIV-1 proteases. However, since the 36th residue is located at a non-active site of the protease and has no direct interaction with any ligands, the structural role of M36I remains unclear. Here, we performed molecular dynamics (MD) simulations of M36I protease in complex with nelfinavir and revealed the influence of the M36I mutation. The results show that M36I regulates the size of the binding cavity of the protease. The reason for the rare emergence of D30N variants in non-subtype B HIV-1 proteases was also clarified from our computational analysis.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17524421     DOI: 10.1016/j.jmb.2007.04.081

Source DB:  PubMed          Journal:  J Mol Biol        ISSN: 0022-2836            Impact factor:   5.469


  26 in total

1.  HIV-1 protease with 20 mutations exhibits extreme resistance to clinical inhibitors through coordinated structural rearrangements.

Authors:  Johnson Agniswamy; Chen-Hsiang Shen; Annie Aniana; Jane M Sayer; John M Louis; Irene T Weber
Journal:  Biochemistry       Date:  2012-03-20       Impact factor: 3.162

2.  Atomistic simulations of the HIV-1 protease folding inhibition.

Authors:  Gennady Verkhivker; Guido Tiana; Carlo Camilloni; Davide Provasi; Ricardo A Broglia
Journal:  Biophys J       Date:  2008-03-28       Impact factor: 4.033

3.  Identification of folding preferences of cleavage junctions of HIV-1 precursor proteins for regulation of cleavability.

Authors:  Hirotaka Ode; Masaru Yokoyama; Tadahito Kanda; Hironori Sato
Journal:  J Mol Model       Date:  2010-05-18       Impact factor: 1.810

4.  Autocatalytic maturation, physical/chemical properties, and crystal structure of group N HIV-1 protease: relevance to drug resistance.

Authors:  Jane M Sayer; Johnson Agniswamy; Irene T Weber; John M Louis
Journal:  Protein Sci       Date:  2010-11       Impact factor: 6.725

5.  Emergence of drug resistance-associated mutations in HIV-1 subtype C protease gene in north India.

Authors:  Mohd Azam; Abida Malik; Meher Rizvi; Supriya Singh; Poonam Gupta; Arvind Rai
Journal:  Virus Genes       Date:  2013-07-26       Impact factor: 2.332

6.  HIV-1 protease codon 36 polymorphisms and differential development of resistance to nelfinavir, lopinavir, and atazanavir in different HIV-1 subtypes.

Authors:  Irene Lisovsky; Susan M Schader; Jorge-Luis Martinez-Cajas; Maureen Oliveira; Daniela Moisi; Mark A Wainberg
Journal:  Antimicrob Agents Chemother       Date:  2010-04-19       Impact factor: 5.191

7.  Modeling effects of human single nucleotide polymorphisms on protein-protein interactions.

Authors:  Shaolei Teng; Thomas Madej; Anna Panchenko; Emil Alexov
Journal:  Biophys J       Date:  2009-03-18       Impact factor: 4.033

8.  Prediction of potency of protease inhibitors using free energy simulations with polarizable quantum mechanics-based ligand charges and a hybrid water model.

Authors:  Debananda Das; Yasuhiro Koh; Yasushi Tojo; Arun K Ghosh; Hiroaki Mitsuya
Journal:  J Chem Inf Model       Date:  2009-12       Impact factor: 4.956

Review 9.  Therapeutic strategies underpinning the development of novel techniques for the treatment of HIV infection.

Authors:  Jian J Tan; Xiao J Cong; Li M Hu; Cun X Wang; Lee Jia; Xing-Jie Liang
Journal:  Drug Discov Today       Date:  2010-01-22       Impact factor: 7.851

10.  Elucidating a relationship between conformational sampling and drug resistance in HIV-1 protease.

Authors:  Ian Mitchelle S de Vera; Adam N Smith; Maria Cristina A Dancel; Xi Huang; Ben M Dunn; Gail E Fanucci
Journal:  Biochemistry       Date:  2013-05-01       Impact factor: 3.162

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.